Efficacy and safety of neoadjuvant chemotherapy with oxaliplatin, 5-fluorouracil, and levofolinate for T3 or T4 stage II/III rectal cancer: the FACT trial-Reference-Cited by-同舟云学术

Efficacy and safety of neoadjuvant chemotherapy with oxaliplatin, 5-fluorouracil, and levofolinate for T3 or T4 stage II/III rectal cancer: the FACT trial

Published:2017-02-01 Issue:3 Volume:79 Page:519-525
ISSN:0344-5704
Container-title:Cancer Chemotherapy and Pharmacology
language:en
Short-container-title:Cancer Chemother Pharmacol

Author:

Koike Junichi,Funahashi Kimihiko,Yoshimatsu Kazuhiko,Yokomizo Hajime,Kan Hayato,Yamada Takeshi,Ishida Hideyuki,Ishibashi Keiichiro,Saida Yoshihisa,Enomoto Toshiyuki,Katsumata Kenji,Hisada Masayuki,Hasegawa Hirotoshi,Koda Keiji,Ochiai Takumi,Sakamoto Kazuhiro,Shiokawa Hiroyuki,Ogawa Shimpei,Itabashi Michio,Kameoka Shingo

Publisher

Springer Science and Business Media LLC

Subject

Pharmacology (medical),Cancer Research,Pharmacology,Toxicology,Oncology

Link

http://link.springer.com/content/pdf/10.1007/s00280-017-3243-7.pdf

Reference33 articles.

1. Cancer Registry and Statistics. Cancer Information Service, National Cancer Center, Japan

2. Folprecht G, Gruenberger T, Bechstein WO et al (2010) Tumour response and secondary resectability of colorectal liver metastases following neoadjuvant chemotherapy with cetuximab: the CELIM randomised phase 2 trial. Lancet Oncol 11:38–47

3. Takahashi T, Shibata Y, Tojima Y et al (2013) Multicenter phase II study of modified FOLFOX6 as neoadjuvant chemotherapy for patients with unresectable liver-only metastases from colorectal cancer in Japan: ROOF study. Int J Clin Oncol 18:335–342

4. Hasegawa J, Nishimura J, Mizushima T et al (2014) Neoadjuvant capecitabine and oxaliplatin (XELOX) combined with bevacizumab for high-risk localized rectal cancer. Cancer Chemother Pharmacol 73:1079–1087

5. Uehara K, Hiramatsu K, Maeda A et al (2013) Neoadjuvant oxaliplatin and capecitabine and bevacizumab without radiotherapy for poor-risk rectal cancer: N-SOG 03 Phase II trial. Jpn J Clin Oncol 43:964–971

Cited by 30 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Outcomes of multimodal treatment including preoperative chemotherapy for upper rectal cancer;Koloproktologia;2023-12-21

2. Neoadjuvant chemotherapy (CAPOX) alone for low- and intermediate-risk stage II/III rectal cancer: Long-term follow-up of a prospective single-arm study;European Journal of Surgical Oncology;2023-12

3. GRECCAR 14 – a multicentric, randomized, phase II–III study evaluating the tailored management of locally advanced rectal carcinoma after a favourable response to induction chemotherapy: Study protocol;Colorectal Disease;2023-09-11

4. Comparison of the pathological response to 2 or 4 cycles of neoadjuvant CAPOX in II/III rectal cancer patients with low/intermediate risks: study protocol for a prospective, non-inferior, randomized control trial (COPEC trial);Trials;2023-06-13

5. Neoadjuvant chemotherapy for treatment patients with rectal cancer with adverse prognostic factors: A review;Journal of Modern Oncology;2022-11-25